Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CeriBellCBLL +3.18%12 3-Year EPS without NRI Growth Rate is 2.70% as of Mar. 2026, which is at its 10-year median of 2.70. GuruFocus rates CBLL with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 658 Medical Devices & Instruments companies, CeriBell ranks worse than 57.6% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 2.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of CeriBell was 2.70% per year. The lowest was 2.70% per year. And the median was 2.70% per year.
CeriBell (NAS:CBLL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
CeriBell 3-Year EPS without NRI Growth Rate Related Terms
CBLL vs TCMD, CERS, SSII: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, CeriBell's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CeriBell 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CeriBell's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where CeriBell's 3-Year EPS without NRI Growth Rate falls into.
CeriBell 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 2.70% mean?
CeriBell (CBLL) has a 3-Year EPS without NRI Growth Rate of 2.70% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CeriBell and its competitors. This is near median its historical median of 2.70. Over the past decade, CeriBell's 3-Year EPS without NRI Growth Rate has ranged from 2.70 to 2.70. According to the industry distribution chart, CeriBell ranks #379 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 57.6%.
Is CeriBell's 3-Year EPS without NRI Growth Rate too high?
CeriBell's current 3-Year EPS without NRI Growth Rate of 2.70% is near median its 10-year median of 2.70. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 2.70. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. CeriBell's value of 2.70% is 66.5% below this industry median. Based on the distribution chart, CeriBell ranks #379 out of 658 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CeriBell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CeriBell's 3-Year EPS without NRI Growth Rate compare to TCMD and CERS?
According to the Medical Devices & Instruments industry distribution chart, CeriBell ranks #379 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places CeriBell in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. CeriBell's value of 2.70% is 66.5% below this benchmark. Historically, CeriBell's own 3-Year EPS without NRI Growth Rate has ranged from 2.70 to 2.70 over the past decade. While the company's 10-year median is 2.70 vs. the industry median of 8.05, CeriBell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CeriBell's current 3-Year EPS without NRI Growth Rate of 2.70% is 66.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CeriBell and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CeriBell's current 3-Year EPS without NRI Growth Rate is 2.70%, which is near median its own 10-year median of 2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CeriBell stock overvalued right now?
CeriBell (CBLL) has a current 3-Year EPS without NRI Growth Rate of 2.70%. The current 3-Year EPS without NRI Growth Rate is 2.70%, which is near median its 10-year median of 2.70 and 66.5% below the Medical Devices & Instruments industry median of 8.05. CeriBell's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For CeriBell (CBLL), the current 3-Year EPS without NRI Growth Rate is 2.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
12GF Score
Get the complete analysis for CBLL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBLL has been successfully added to your 
